Journal article
Trends in Intra-Aortic Balloon Pump Use in Cardiogenic Shock After the SHOCK-II Trial
E Nan Tie, D Dinh, W Chan, DJ Clark, AE Ajani, A Brennan, M Dagan, N Cohen, E Oqueli, M Freeman, C Hiew, JA Shaw, CM Reid, DM Kaye, D Stub, SJ Duffy
American Journal of Cardiology | Published : 2023
Abstract
Myocardial infarction complicated by cardiogenic shock (MI-CS) has a poor prognosis, even with early revascularization. Previously, intra-aortic balloon pump (IABP) use was thought to improve outcomes, but the IABP-SHOCK-II (Intra-aortic Balloon Pump in Cardiogenic Shock-II study) trial found no survival benefit. We aimed to determine the trends in IABP use in patients who underwent percutaneous intervention over time. Data were taken from patients in the Melbourne Interventional Group registry (2005 to 2018) with MI-CS who underwent percutaneous intervention. The primary outcome was the trend in IABP use over time. The secondary outcomes included 30-day mortality and major adverse cardiovas..
View full abstractGrants
Funding Acknowledgements
The Melbourne Interventional Group acknowledges funding from Abbott Vascular (Chicago, Illinois), AstraZeneca (Cambridge, United Kingdom), Bristol-Myers Squibb (New York, New York), and Pfizer (New York, New York). These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication.